Commentary on a recent review of lithium toxicity: what are its implications for clinical practice?

BMC Medicine

Paul Grof³  Michael Bauer¹  Bruno Müller-Oerlinghausen² 

[1] Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;Drug Commission of the German Medical Association, Berlin, Germany;Mood Disorders Center of Ottawa and Department of Psychiatry, University of Toronto, Canada

关键词: meta-analysis;    thyroid;    nephrotoxicity;    parathyroid;    renal effects;    bipolar disorder;    Lithium;   

Others  :  857317
DOI  :  10.1186/1741-7015-10-132

 received in 2012-09-24, accepted in 2012-11-02,  发布年份 2012

【 摘 要 】

A recent paper by McKnight et al. in The Lancet has provided the first formal meta-analysis of the more common adverse reactions to lithium. The authors analyzed 385 studies and focused mainly on the harmful effects of lithium on the kidney, the thyroid and parathyroid glands, body weight, skin and congenital malformations. Their contribution is important and welcome, but as a guide for practice, it needs to be complemented by other relevant observations and individual patient-focused perspectives.

The findings from that meta-analysis somewhat underestimate the renal side-effects, and distort to some degree or exclude other adverse effects. The glomerular filtration rate is reduced but not more than 0 to 5 ml/min/year of observation; this may not fully reflect the present state of knowledge. A quarter of patients in the study had abnormalities of the thyroid and/or parathyroid gland, and lithium was found to increase body weight significantly less than did olanzapine. Unfortunately, the authors did not consider the observations from spontaneous reporting systems, which may have changed the picture.

We feel that some specific limitations of the study were related to the inclusion of patients regardless of adequacy of treatment, quality of monitoring, drug combinations, age and sex, and stabilization response.

【 授权许可】

   
2012 Müller-Oerlinghausen et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Pfennig A, Bschor T, Baghai T, Bräunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M: [S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations] (in German). Nervenarzt 2012, (83):568-86.
• [2]Hirschowitz J, Kolevzon A, Garakani A: The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiatry 2010, 18:266-278.
• [3]Bauer M, Grof P, Müller-Oerlinghausen: Lithium in Neuropsychiatry. The Comprehensive Guide.. London-Abingdon,,Informa Healthcare; 2006.
• [4]McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR: Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012, 379:721-728.
• [5]Presne C, Fakhouri F, Noël LH, Stengel B, Even C, Kreis H, Mignon F, Grünfeld JP: Lithium-induced nephropathy: rate of progression and prognosis factors. Kidney Int 2003, 64:585-592.
• [6]Bendz H, Schön S, Attman PO, Aurell M: Renal failure occurs in chronic lithium tratment but is uncommon. Kidney Int 2009, 77:219-224.
• [7]Ibbeken C, Becker JU, Baumgärtner MW: [Renal side effects of long-term lithium therapy] (in German). Dtsch Med Wschr 2012, 137:143-148.
• [8]Grünfeld J-P, Rossier BC: Lithium nephrotoxicity revisited. Nat Rev Nephrology 2009, 5:271-278.
• [9]Bassilios N, Martel P, Godard V, Froissart M, Grünfeld JP, Stengel B, Néphropar Réseau: Monitoring of glomerular filtrating rate in lithium-treated outpatients - an ambulatory laboratory database surveillance. Nephrol Dial Transplant 2008, 23:562-565.
• [10]Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B: A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiat Scand 2012, 126:186-197.
• [11]Biel MG, Pesselow E, Mulcare L, Case BG, Fieve R: Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipol Disord 2007, 9:435-442.
• [12]Gründer G, Hippius H, Carlsson A: The "atypicality" of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009, 8:197-202.
• [13]Verdoux H, Cougnard A, Auleley GR, Deligne J, Blum-Boisgard C, Bégaud B, Tournier M: Antipsychotic use patterns in persons initially treated with mood stabilizers: A naturalistic study. Pharmacopsychiat 2010, (43):17-23.
• [14]Greil W, Häberle A, Haueis P, Grohmann R, Russmann S: Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the international AMSP project between 1994 and 2009. J Affect Disord 2012, 136:534-542.
• [15]Ghaemi SN: Mood Disorders. 2nd edition. Lippincott, Williams and Wilkins. Philadelphia; 2008.
• [16]Gentile S: Atypical antipsychotics for the treatment of bipolar disorder. More shadow than light. CNS Drugs 2007, 21:367-387.
• [17]Müller-Oerlinghausen B: [Are atypical antipsychotic drugs the first line treatment for bipolar disorders? Contra] (in German). Nervenarzt 2012. DOI 10.1007/s00115-012-3619-1
• [18]Grof P, Müller-Oerlinghausen B: A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipol Disord 2009, 11(Suppl 2):10-19.
• [19]Malhi GS, Berk M: Is the safety of lithium no longer in the balance? Lancet 2012, 379:690-692.
• [20]Grof P: Sixty years of lithium responders. Neuropsychobiology 2010, 62:8-16.
• [21]International Group for The Study of Lithium Treated Patients [http://www.igsli.org] webcite